Peripheral Neuropathy Trial, Recruiting NCT07473635 Sponsor: Bo Biering-Soerensen Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Peripheral Neuropathy Trial, Recruiting

NCT07473635
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are over 18 years old
  • People who have been diagnosed with Complex Regional Pain Syndrome (CRPS) type 1 or 2 in one arm or one leg, confirmed using a specific set of diagnostic guidelines called the Budapest research criteria
  • People who have had this condition for at least 6 months
  • People who consider CRPS to be their main or most significant pain condition
  • People who have been on a steady, unchanged pain medication routine (including any extra medications taken as needed) for at least one month before the study, and who plan to keep that routine the same throughout the study
  • Women who have not yet gone through menopause and are using an approved method of contraception
  • People who can speak, read, and understand Danish

Who may not be able to join:

  • People who are allergic to botulinum toxin A (commonly known as Botox)
  • People who have received botulinum toxin A treatment for any reason within the 3 months before the study begins
  • People who have been diagnosed with myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis (ALS), or any other condition that makes it difficult to separate CRPS-related pain from other pain (confirm with trial site)
  • People who currently have an active infection in the affected arm or leg
  • People who do not plan to continue with physical therapy, psychological therapy, or any other non-medication-based pain treatment during the study
  • People who have used a skin-applied pain relief treatment (such as lidocaine patches) within one week before the study starts, or who have had capsaicin patches applied to the affected area within 3 months before the study starts
  • People who have a psychiatric condition that the trial investigators believe would affect their ability to take part in the study
  • People who drink alcohol in amounts exceeding the limits recommended by the Danish Ministry of Health
  • People who are currently misusing illegal drugs
  • People who are pregnant, breastfeeding, or planning to become pregnant during the study period
  • People who have any other health condition or personal circumstance that the trial investigators believe would make safe and complete participation in the study difficult

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +45 38633030

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Bo Biering-Soerensen
Registry
ClinicalTrials.gov
Start date
7 January 2026
Est. completion
1 July 2026

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

Recruitment rate; Screening-to-enrolment ratio; Study completion rate; Completeness of study data

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov